TY  - JOUR
A1  - Jäger, Simon U.
A1  - Schäffeler, Elke
A1  - Winter, Stefan
A1  - Tremmel, Roman
A1  - Schölmerich, Jürgen
A1  - Malek, Nisar
A1  - Stange, Eduard F.
A1  - Schwab, Matthias
A1  - Wehkamp, Jan
T1  - Influence of NOD2 variants on Trichuris suis ova treatment outcome in Crohn’s disease
T2  - Frontiers in pharmacology
N2  - A recent randomized study of whipworm Trichuris suis ova (TSO) in ileal Crohn’s disease failed to demonstrate a clinical benefit compared to placebo after 12 weeks. Nonetheless, it has recently been shown that the spontaneous small intestinal inflammatory changes in Nod2-/- (Nucleotide-binding oligomerization domain 2) mice could be substantially ameliorated when these mice were colonized by Trichuris muris. Those and complementary epidemiologic findings in humans lead to the hypothesis that helminths may be advantageous only in patients carrying defective NOD2 variants. Thus, 207 participants of the TSO trial were retrospectively genotyped for six functional NOD2 genetic variants to evaluate whether the treatment outcome differed in patients carrying NOD2 variants. We observed no significant association of the NOD2 variants or their haplotypes with clinical outcome after TSO treatment.
KW  - Trichuris suis ova
KW  - Crohn’s disease
KW  - NOD2
KW  - helminths
KW  - innate immunity
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54387
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-543878
SN  - 1663-9812
N1  - Copyright © 2018 Jaeger, Schaeffeler, Winter, Tremmel, Schölmerich, Malek, Stange, Schwab and Wehkamp. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
VL  - 9
IS  - Article 764
PB  - Frontiers Media S.A.
CY  - Lausanne
ER  -